Table of Contents

Differential patterns of gene expression and CD20 localization by GA101 compared with rituximab suggests binding to functionally distinct CD20 subpopulations on B-cell lymphoma cell lines

NE Oncology Issue - April 2012 Niederfellner G, et al. ASH 2011: Abstract 3721 Background The precise molecular mechanism(s) by which GA101 exerts its effect on B-cells has not yet been elucidated. Niederfellner and colleagues investigated the differences in direct...

Second-line therapies after treatment with fludarabine, cyclophosphamide, and rituximab (FCR) or fludarabine and cyclophosphamide alone (FC) for CLL within the CLL8 protocol of the German CLL Study Group (GCLLSG)

NE Oncology Issue - April 2012 Cramer P, et al. ASH 2011: Abstract 2863 Background The CLL8 trial of physically fit, treatment-naïve chronic lymphocytic leukemia (CLL) patients was the first study to show not only an increase in complete remission (CR) rates and...

Download Journal


Canadian Perspectives

James Johnston, MD, FRCPC
Dr. James Johnston is a professor in the Department of Internal Medicine at the University of Manitoba and a hematologist at CancerCare Manitoba. He is primarily interested in the treatment of chronic lymphocytic leukemia (CLL) and is responsible for the CLL clinic at CancerCare Manitoba. He is also the Clinical Director of the Manitoba CLL Tumour Bank. Dr. Johnston’s research activities relate to the epidemiology of CLL and to the mechanism of action of anti-tumour agents in this disease. He is involved in a number of educational activities related to CLL and with Dr Spencer Gibson organizes the “Canadian CLL Meeting” which is held annually in Winnipeg.

Laurie H. Sehn, MD, MPH
Dr. Laurie H. Sehn is a Clinical Assistant Professor at the BC Cancer Agency and the University of British Columbia in Vancouver. She has been a medical oncologist and clinical investigator with the Lymphoma Tumour Group since 1998. Dr. Sehn has served on the Board of Directors of Lymphoma Foundation Canada (LFC) since 2002 and is currently Director of Research Fellowships for the LFC. Dr. Sehn’s research interests include all of the lymphoid cancers, with particular interest in the biology and treatment of large-cell lymphoma, the application of new imaging techniques such as PET scanning to lymphoma management, and innovative new approaches to treatment.

C. Tom Kouroukis, MD
Dr. C. Tom Kouroukis graduated from the University of Toronto and completed training in Internal Medicine, Hematology and MSc (Health Research Methodology) training at McGill and McMaster Universities. He was awarded a National Cancer Institute of Canada Clinical Research Fellowship. He is a hematologist at the Juravinski Cancer Centre/Hamilton Health Science, Chair of the Hematology Disease Site Team, Head of the Division of Malignant Hematology, and Associate Professor in the Department of Oncology. He is Co-chair of the Hematology Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative and Chair of the Stem Cell Committee of Cancer Care Ontario. His research interests include the care of older patients with hematological cancers, the impact and evaluation of co-morbidity in older cancer patients, clinical trials, and practice guideline development.

Investigator Commentaries

John C. Byrd, MD
Dr. John Byrd is the D. Warren Brown Chair of Leukemia Research and Director of the Division of Hematology at The Ohio State University, OH, USA. Dr. Byrd is an active member of the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group B) and the CLL Research Consortium. Dr. Byrd has a long track record of preclinical and clinical drug development in chronic lymphocytic leukemia and related diseases. He has over 250 peer reviewed publications related to his work.

Jennifer A. Woyach, MD
Dr. Jennifer Woyach completed her Internal Medicine Residency and Chief Medical Residency at The Ohio State University (OSU), OH, USA and is currently in the third year of her hematology and oncology fellowship at OSU. Her clinical and research interests are in chronic lymphocytic leukemia (CLL) and lymphoma. She is also a member of the CLL Experimental Therapeutics Laboratory at OSU and is the Junior Investigator on the Leukemia Committee of the Alliance for Clinical Trials in Oncology.

Mathias J. Rummel, MD, PhD
Mathias J. Rummel is the head of the Department for Hematology at the Clinic for Hematology and Medical Oncology at the Justus-Liebig University-Hospital, Giessen, Germany. Professor Rummel studied medicine at J.W. Goethe University Hospital in Frankfurt, Germany, obtaining his licence to practice medicine in 1995. Following this, he completed his doctoral degree and residency, obtained board certification in internal medicine, and was awarded his PhD from J.W. Goethe University Hospital. Professor Rummel’s current research focuses on novel treatment approaches in hematological malignancies, most notably follicular and other indolent lymphomas as well as hairy cell leukemia and also immune thrombocytopenic purpura (ITP). He is the chair of the Study group indolent Lymphomas (StiL) and principal investigator of several on-going clinical trials in leukemias, lymphomas, and ITP. He is actively involved in a number of professional scientific societies, he is a reviewer for a number of journals, and has several published book chapters and papers to his credit.